Cargando…
Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials
AIM: We conducted this systematic review and meta-analysis to investigate the efficacy and safety of gefapixant, a novel P2X3 receptor antagonist, in patients with chronic cough. METHODS: We searched four databases for randomized controlled trials (RCTs). We assessed the cough frequency, severity, t...
Autores principales: | Abu-Zaid, Ahmed, Aljaili, Aseel Khalid, Althaqib, Amnah, Adem, Fatima, Alhalal, Doaa Ali, Almubarak, Amena Faiq, Aldughaither, Saud Musaab, Alghabban, Sarah Ali, Alfaraj, Ghaidaa, Masoud, Ahmed Taher, Alsuhaibani, Nujud Abdullah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109686/ https://www.ncbi.nlm.nih.gov/pubmed/34012479 http://dx.doi.org/10.4103/atm.ATM_417_20 |
Ejemplares similares
-
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023) -
Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
por: Chuang, Min-Hsiang, et al.
Publicado: (2023) -
Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023) -
The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023) -
P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
por: Cui, Wen-Wen, et al.
Publicado: (2022)